Purpose: USP-11, a member of the ubiquitin-specific protease family, has emerged as an essential regulator of double-strand break repair. Few studies have shown that silencing USP-11 led to hypersensitivity to poly(ADP-ribose) polymerase inhibition, ionizing radiation, and DNAdamaging agents. We sought to examine the predictive and prognostic relevance of USP-11 in patients treated with neoadjuvant systemic therapy (NST) for breast cancer.
R ecent evidence implicates a substantial commitment of the cellular DNA damage response (DDR) machinery to the synthesis, recognition, and hydrolysis of ubiquitin chains at DNA damage sites. Ubiquitin, the highly conserved 76-amino-acid protein, once linked to the target protein by a cascade of enzymes including ubiquitin-activating enzyme (E1), ubiquitin-conjugated enzyme (E2), and ubiquitin ligase (E3), can initiate a number of posttranslational cellular processes. 1 The hydrolysis of the isopeptide bond connecting ubiquitin to a substrate protein is performed by deubiquitinating enzymes (DUBs), and this renders target proteins able to escape proteasome degradation and thus resume their original designated functions. 2 Two families of DUBs have been identified, all of which exhibit specificity for one type of ubiquitin chain isoform. 3Y5 USP-11, located on the X chromosome, 6 is a member of USP subclass of the ubiquitin-specific protease (UBP) family. 7 Proteins in the UBP family differ in length but possess conserved domains such as Cys box and His box, responsible for the catalytic activity of UBPs. 1 USP-11 is primarily localized in the nucleus of nondividing cells and was found throughout mitotic cells. 8 USP-11 deubiquitylates specific substrates that play key roles in correct microtubule nucleation (RanBPM) 8 ; antigenpresenting cell function (RELB) 9 ; inflammation, immunity, cell proliferation and apoptosis (tumor necrosis factor >Yinduced nuclear factor JB, and IKKa/p53 signaling pathway) 10, 11 ; and E7-modulated cell growth and transformation (HPV-16E7). 12 Furthermore, USP-11 has emerged as an essential regulator of double-strand break (DSB) repair through its interaction with BRCA2 13 and by recruitment of a subset of DSB repair proteins including 53BP1 and RAD51 to repair foci. 14 More importantly, few studies have shown that silencing USP-11 led to spontaneous DDR activation in otherwise undamaged cells and hypersensitivity to poly(ADP-ribose) polymerase (PARP) inhibition, ionizing radiation (IR), and genotoxic agents including bleomycin, cisplatin, and mitomycin C, which induce DNA damage via homologous recombination (HR)Ydependent pathways. 13, 14 However, there are no clinical data on the effectiveness of neoadjuvant systemic therapy (NST) in breast cancers with USP-11 low and high expression and also if USP-11 expression is predictive of improved long-term survival in sporadic breast cancers. Thus, we postulated that tumors with low USP-11 expression would be defective in HR repair and therefore more sensitive to NST. We conducted this retrospective analysis to determine the pathological complete response (pCR) rates following NST in breast cancer tumors with high versus low USP-11 expression. Our secondary endpoints included disease-free survival (DFS) and overall survival (OS).
MATERIALS AND METHODS

Patient Population
The prospectively maintained Breast Cancer Management System research database of The University of Texas M.D. Anderson Cancer Center (MDACC) identified 56 consecutive women treated between 1999 and 2004 and who had prechemotherapy diagnostics core biopsy tissue available. Initial clinical stages of all patients were revised and based on the seventh edition of the American Joint Committee on Cancer staging ORIGINAL ARTICLE criteria. 15 This study was approved by the institutional review board at MDACC. Patient clinical data, tumor characteristics, lymph node status, chemotherapy type, and survival data were retrieved from the clinical database and correlated with USP-11 status, pCR, and survival outcomes.
Pathological Assessment
All pathological specimens were reviewed by designated breast pathologists at MDACC. Histologic type and tumor grade were defined according to the World Health Organization classification system 16 and the modified Black and Speer's 17 nuclear grading system, respectively. Immunohistochemical (IHC) analysis was used to determine estrogen receptor (ER) and progesterone receptor (PR) status. Tumors were considered ER-or PR-positive if 10% of cells or greater showed nuclear staining. Human epidermal growth factor receptor 2 (HER2) positivity was defined as 3+ receptor overexpression by IHC staining and/ or as gene amplification (gene copy ratio of 92.0 of HER2: CEP17) found on fluorescence in situ hybridization. Pathological complete response was defined as the absence of any invasive disease in the breast, and the absence of micrometastasis or macrometastasis in the ipsilateral axillary lymph nodes.
Expression of USP-11 was analyzed on prechemotherapy diagnostic biopsy samples using anti-USP-11 (C-term) polyclonal antibody 18 by IHC. The degree of USP-11 overexpression on IHC determined how patients were grouped. Percentage of overall cytoplasmic expression in tumor cells was recorded (no nuclear staining was detected) ( Fig. 1) . Similarly, the intensity was scored as 0 (no expression), 1 (weak expression), 2 (moderate expression), and 3 (strong expression). Percentage (P) and intensity of cytoplasmic expression were multiplied to generate a numerical score, and the resulting score was used to dichotomize the tumors. Martingale residual suggested that a cutoff of 250 is appropriate for OS. Low USP-11 expression was defined as less than 250 (n = 40), and high USP-11 expression was defined as 250 or greater (n = 16).
Treatment
All patients were treated with anthracycline plus paclitaxelbased NST as per standard clinical protocols used in the institution. Thirty-six patients received sequential weekly paclitaxel 80 mg/m 2 in 12 courses followed by 4 to 6 courses of FAC (5-fluorouracil 500 mg/m 2 , doxorubicin 50 mg/m 2 , and cyclophosphamide 500 mg/m 2 ); 19 patients (34%) received sequential weekly paclitaxel 80 mg/m 2 in 12 courses followed by 4 to 6 courses of FEC (5-fluorouracil 500 mg/m 2 , epirubicin 75 mg/m 2 , and cyclophosphamide 500 mg/m 2 ). One patient received only weekly paclitaxel Â 12. Of 15 patients who had HER2-positive breast cancer, 6 (40%) also received i.v. trastuzumab during NST.
After completion of NST, all patients underwent definitive breast surgery and axillary lymph node dissection or sentinel node dissection. Surgical intervention was breast-conserving surgery for 34% of patients (n = 19) and mastectomy for 66% of patients (n = 37). When appropriate, locoregional radiotherapy and hormone therapy were given after surgery.
Statistical Analysis and Outcome Measures
The demographic and clinical characteristics were summarized and compared between the 2 groups, defined by USP-11 status (low vs. high expression) with the W 2 test for categorical variables and Kruskal-Wallis test or Wilcoxon rank sum test for continuous variables. The W 2 test or Fisher exact test was used to identify the significant factors predictive of a pCR.
Disease-free survival was calculated from the surgery date until the first date of documented disease recurrence or death or the date to first metastasis or death or last follow-up. Overall survival was calculated from the time of initial diagnosis until the date of death from any cause or last follow-up. Martingale residual was calculated using Cox model to define an appropriate cutoff point for dividing patients using USP-11 expression. Overall survival and DFS were estimated using the Kaplan-Meier method, and the comparisons between or among patients' characteristics groups were assessed using log-rank test (Fig. 2 ). 
RESULTS
Patient demographics and pretreatment clinical characteristics are summarized in Table 1 . Patients who presented with clinical tumor stage I/II and had negative lymphovascular invasion (LVI) were more likely to have low USP-11 tumor cell expression. USP-11 expression was not linked to any other clinical-phenotypic characteristics of breast cancer tumors.
Response to NST
Overall, pCR was achieved by 15 patients (26%), a response rate that is consistent with our previous experience in a larger randomized study using similar NST. 19 The pCR rates in various subgroups in relation to the various clinical and biological factors are shown in Table 2 . Confirming the previous studies, 20,21Y23 nonwhites and patients whose tumors were ER/ PR-negative, triple-negative, or with negative LVI appeared to be more likely to have a pCR. USP-11 status did not significantly influence the pCR rate. Eleven patients (27.5%) achieved a pCR in the low-USP-11 group compared with 4 patients (25%) in the high-USP-11 group (P = 1.00).
Survival Estimates
Median follow-up of all patients was 7.4 years (range, 0.6Y17.3 years). Overall, 19 breast cancer recurrences or deaths (34%) were observed: 10 in the low-USP-11 group versus 9 in the high-USP-11 group. The estimated 5-year DFS rates were 77.2% (95% confidence interval [CI], 60.7%Y87.4%) in the low-USP-11 group versus 46.7% (95% CI, 21.2%Y68.7%) in the high-USP-11 group (P = 0.009) ( Table 3) .
Overall, patients who achieved a pCR had a better DFS than did patients who did not (5-year rate, 93.3% [95% CI, 61.3%Y99.0%] vs. 59.6% [95% CI, 42.7%Y73.0%]; P = 0.04). In univariate analyses, age older than 50 years, black race, and clinical stage III/IV were associated with a significantly increased risk of recurrence. The multivariate Cox proportional hazards model showed that patients who did not achieve a pCR and patients with high-USP-11Yexpressing tumors had an increased risk of recurrence (odds ratio [OR], 5.16; 95% CI, 1.16Y23.07; P = 0.03; and OR, 3.87; 95% CI, 1.51Y9.93; P = 0.005, respectively) ( Table 4 ).
There were a total of 14 deaths (25%): 5 in the low-USP-11 group versus 9 in the high-USP-11 group. The 5-year OS estimates were 87.0% (95% CI, 71.6%Y94.4%) in the low-USP-11 group compared with 66.7% (95% CI, 37.5%Y84.6%) in the high-USP-11 group (P = 0.0002). In univariate analyses, age older than 50 years, black race, and clinical III/IV stage was associated with an increased risk of death. The multivariate Cox proportional hazards model showed that clinical stage I/II was associated with a lower risk of death (OR, 0.25; 95% CI, 0.08Y0.78; P = 0.02), whereas patients with high-USP-11Y expressing tumors had a higher risk of death (OR, 6.03; 95% CI, 2.00Y18.17; P = 0.001) ( Table 5 ).
DISCUSSION
Our data indicate that USP-11 is not a predictor of pCR after anthracycline-taxaneYcontaining NST for breast cancer; however, this does not exclude the possibility of hypersensitivity to other DNA-damaging agents including platinums, PARP inhibitors, mitomycin, and bleomycin as suggested by previous preclinical studies. 13, 14 We show that low USP-11 expression was independently correlated with better survival outcomes following NST. Predictions of pCR have been attempted on the basis of tumor expression of proliferation and apoptosis markers, 24 endocrine and growth factors, oncogenes, 25 genes involved in the ubiquitin-proteasome pathway, and DNA repair and cell death regulators. 26 And to achieve a greater predictive value, multiple gene expression profiles are examined simultaneously and correlated with pCR and survival. 27Y33 Besides the ER/PR-negative status, lack of p53 expression, high baseline proliferative, and apoptotic indices, 34Y37 only few additional single biomarkers (eIF4E, 38 CXCR4, 39 ALDH1, 40 BCL-2, 27 aBcrystallin, 41 KRT13/NFAT5) 42 have been shown to possess a sufficient predictive/prognostic value to render them clinically useful. In this study, we failed to show that USP-11 has a predictive value; however, we demonstrate that USP-11 deubiquitinase can be a potential prognostic marker of subsequent survival benefit.
Transcriptional and posttranslational modification and degradation of proteins by the ubiquitin-proteasome system are key regulatory events in cellular responses to various stimuli. Recently, identification of mutations in a E3 ubiquitin ligase, RNF168, as the underlying genetic disorder of the DNA repair deficiency disorder, RIDDLE syndrome, has brought to light a critical role for the ubiquitin system in regulating the cellular DSBs. The finding that RNF168 functions downstream of RNF8 to orchestrate the recruitment of repair proteins, such as BRCA1 and 53BP1, to sites of DNA damage suggests that ubiquitin cascade regulates the spatial relocalization of DSB repair proteins. 43 Although much progress has been made in characterizing enzymes that link ubiquitin to proteins, our understanding of DUBs is less well developed, with only few enzymes identified. 44Y46 Preclinical studies suggest that DUBs play an important role in maintaining the delicate balance in DDR by regulating p53 expression 11 and recruitment of DNA repair/ checkpoint proteins to DSB foci 43,47,48 through ubiquitin conjugation/deconjugation or ubiquitin turnover. This notion was supported by 2 observations: first, when cells are treated with proteasome inhibitor MG132, which functions to reduce the pools of free ubiquitin, the formation of IR-induced RNF168 foci was affected, 49 and second, overexpression of the deubiquitylating enzyme USP-3 blocked RNF168 accumulation at sites of DNA breaks. 50 It is also clear that defective ubiquitylation/ deubiquitylation activities at DSBs significantly increase predilection to tumorigenesis or increase hypersensitivity to IR or DNA-damaging agents. 51Y55 Given the DUB impact on the relative ratios of different ubiquitin linkages of DNA repair proteins found at DSBs, one would expect that cells with low USP-11 expression have increased sensitivity to NST and therefore higher pCR rates and better survival outcomes. In this study, we failed to show any pCR difference, and intriguingly, patients with low USP-11 expression had tumors with negative LVI, presented at an earlier stage (stage I/II), and had better survival outcomes. It is tempting to speculate that USP-11Ylow cells with a defective DNA repair protein recruitment compensate by up-regulating the MRN/MDC1/ATM pathways 56 or BRCA1-BARD1 domain. 57 This phenomenon is supported by the fact that proteins may contain both a DUB domain and ligase domain in a single-polypeptide chain. For example, BRCA1-RAP80 complex contains both BRCC36-encoded K63-specific DUB activity and BRCA1-derived K6-specific E3 ligase activity, raising the possibility that ''ubiquitin editing'' activities may be performed by different members of the same complex. It is also noteworthy to mention that, of factors associated with low USP-11 expression (stage I/II and negative LVI), only LVI was found to be related to pCR but not the tumor stage, as we know from the previous studies that tumor stage is one of the predictive factors for pCR. Therefore, it is possible that the lack of association between USP-11 expression, tumor stage, and pCR could well be related to small sample size. Future studies with larger sample size need to be conducted to delineate the predictive versus prognostic implications of USP-11 expression. If correlation between USP-11 expression and pCR or survival is confirmed, then we can explore inhibition of USPs as a novel therapeutic strategy. For example, the curcumin-like derivative HO-3867, diarylidenyl piperidone compound, has shown promising activity in preclinical studies on a number of cell types. 58 In ovarian carcinoma cells, HO-3867 has been shown to decrease levels of both USP-2a and its targets FASN and FAK, along with a concomitant reduction in oncogenic behaviors, such as migration and invasion. Using a high-throughput activitybased assay, Tian 59 and colleagues have identified a novel and selective inhibitor of USP-7, paving the way for identification and characterization of additional USP-targeted agents. Further delineation of how DUBs themselves are regulated by phosphorylation, ubiquitination and protein-protein interactions will likely identify additional strategies for clinical intervention. BRCA1 and BRCA2 are tumor suppressor genes that play an important role in mediating the DDR of DSBs by HR. 60 BRCA1 has been shown to be required for the activation of both S-and G2/M-phase cell-cycle arrest after DNA damage, the latter being dependent on prior phosphorylation of BRCA1 by the master checkpoint kinase ATM (ataxia telangiectasia mutated). 61 BRCA1 has also been shown to interact with multiple DNA repair/recombination proteins, including RAD51, the RAD50/MRE11/Nibrin complex, Bloom's helicase, and the Fanconi D2 protein. 62 The major role of BRCA2 is regulation of RAD51 filament formation and activity, which works as a key enzyme catalyzer in HR. 63 Cells lacking BRCA1 or BRCA2 are unable to repair DSBs by HR and die. Therefore, combining PARP (a DNA repair enzyme) inhibition with tumors that have defective BRCA1 or BRCA2 proteins exerts a ''chemical synthetic lethality.'' 64, 65 Likewise, in vitro studies have shown enhanced cytotoxicity to multiple DNA-damaging agents and PARP inhibitors in USP-11Ysilenced cells similar to that observed when BRCA1 is silenced. 13, 14 The question as to whether USP-11Ysilenced tumors with BRCA1 or BRCA2 dysfunction behave in the same way as BRCA1-mutant or USP-11Ysilent tumors remains unresolved. The preclinical evidence suggests that hypersensitivity to DNA-damaging agents in USP-11Ysilenced cells is dependent on intact BRCA2. 13 The interaction between BRCA1 and USP-11 has not been investigated yet; however, a recent study reported that the DSB repair function of USP-11 was independent of the BRCA1 localization. 14 The latter study also detected that RAD51 foci had an accelerated disappearance in USP-11Ysilenced cells, indicating an inability to maintain a sufficient RAD51 filament to facilitate HR repair via BRCA2 signaling pathway. Mass spectrometry results indicate that USP-11 also interacts with a large number of proteins including the transcriptional elongation factors TCEAL1 and 4, other DUBs including USP-7, the NRF2 regulatory protein KEAP1, 66 and p53. 11 Therefore, it is possible that the BRCA1/2 interaction provides a mechanism to recruit USP-11 to DSBs where it can act on other substrates to exert its prosurvival functions. One therapeutically relevant intervention for future studies could be to identify the USP-11 targets mediating its repair function and also to assess the synthetic lethality index in BRCA1/2-and USP-11Ymutant breast tumors exposed to DNA-damaging agents or in cells that are resistant to PARP inhibitors.
Several limitations must be considered when interpreting the results of our study. Our study was a retrospective analysis with small sample size. Our study does not address whether a posttreatment change in USP-11 expression would be predictive of a pCR or survival. Because of small sample size, we could not evaluate the prognostic significance of USP-11 in a separate cohort of triple-negative (TN) tumors. In addition, USP-11 staining pertained only to cytoplasm but not to nucleus in all of the breast tumor samples, which may have resulted in differential outcomes. However, it is an important pilot study in that it identifies possible in vivo biological effects of USP-11 in the ongoing research for predictive molecular markers. It also serves to illustrate the shortcomings of cell lineYbased studies and the need to validate the data on human tissue studies.
In summary, we did not find a correlation between USP-11 expressions in tumor cells and pCR, which is traditionally associated with prognosis. However, our study demonstrates that USP-11 has an independent prognostic impact in patients treated with NST. The lack of association of USP-11 status and pCR in our study may reflect the small sample size of the cohort. It remains to be determined if mutation of the catalytically active site of USP-11 could cause disruption of protein interactions, accounting for the DSB repair defect seen in USP-11Ysilenced cells. Future experimental models and clinical studies need to be conducted to investigate the in vivo biological targets of USP-11 and perhaps using USP-11 as a potential biomarker for chemosensitive phenotype in patients treated with PARP inhibitors or other DNA-damaging agents.
